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ABSTRACT: Macrophage scavenger receptor A (SR-A) is a multifunctional, multiligand pattern recognition
receptor with roles in innate immunity, apoptotic cell clearance, and age-related degenerative pathologies,
such as atherosclerosis and Alzheimer’s disease. Known endogenous SR-A ligands are polyanionic and
include modified lipoproteins, advanced glycation end products, and extracellular matrix proteins. No native
plasma ligands have been identified, but it is known that SR-A recognition of unidentified serum components
mediates integrin-independent macrophage adhesion, which may drive chronic local inflammation. In this
study, we used a high-throughput fractionation and screening method to identify novel endogenous SR-A
ligands that may mediate macrophage adhesion. SR-A was found to recognize the exchangeable apolipo-
proteins A-I and E (apo A-I and apo E, respectively) in both lipid-free and lipid-associated form, suggesting
the shared amphipathic R-helix as a potential recognition motif. Adhesion of RAW 264.7 macrophages
to surfaces coated with apo A-I and apo E4 proved to be integrin-independent and could be blocked by anti-
SR-A antibodies. The presence of apo A-I and apo E in pathological deposits, such as atherosclerotic lesions
and neurotoxic Alzheimer’s plaques, suggests a possible contribution of SR-A-dependent adhesion of
macrophages to an inflammatory microenvironment.
Scavenger receptor A (SR-A)
1 is a multifunctional, multi-
ligand receptor expressed mainly by myeloid cells, which plays a
role both in innate immune defense and removal of modified or
aged self and has been termed molecular flypaper for its low-
affinity, broad specificity ligand binding capacities (1-5). Most
known SR-A ligands are exogenous compounds discovered and
defined by their ability to inhibit binding of receptor to the
archetypal ligand acetylated LDL (2). The majority of endogen-
ous SR-A ligands are connected to age-related degenerative
diseases, oxidized lipoproteins being the driving force behind
atherosclerosis, AGE-modified proteins resulting from diabetic
glucose overload, and β-amyloid fibrils representing major
components of neurotoxic Alzheimer’s plaques (6, 7). A char-
acteristic shared by all known SR-A ligands is their structurally
defined,repetitiveanionicchargedistribution(2).Ligandbinding
and specificity are controlled by a positively charged stretch of
lysines in the collagenous binding domain of the receptor (8, 9),
and receptor engagement is followed by endocytic uptake,
dissociation of the receptor-ligand pair at acidic pH, and
lysosomal degradation (10-12).
Macrophage retention within tissues relies on both metal ion-
dependent and -independent mechanisms, the former including
integrins and selectins and the latter scavenger receptors and
immunoglobulins (13,14).Prolongedorpathologicalretentionof
macrophages may create an inflammatory microenvironment,
which in many cases drives disease, as seen for atherosclerosis,
neurodegeneration, or diabetes-induced nephropathy (15). Pre-
vious studies established a role for SR-A in integrin-independent
adhesionofmacrophagestoanuncharacterisedserumligand(16).
Subsequent adhesion studies have implicated SR-A in adhesion
of macrophages to various extracellular matrix molecules, includ-
ing glycated type IV collagen in diabetic patients, denatured
type I and II collagens, and the proteoglycans biglycan and
decorin (17-19).
To identify plasma-borne endogenous SR-A ligands that
contributetoSR-A-mediatedmacrophageadhesion,wescreened
human plasma for candidate ligands and tested their ability to
sustain macrophage adhesion. Identification of single molecules
from a highly complex mixture such as plasma requires a
combination of separation techniques to reduce complexity and
a stringent large-scale screening method. As the whole-cell
adhesion assays or standard ligand competition assays used to
identify most known SR-A ligands are poorly adapted to multi-
sample analyses, a rapid high-throughput screening assay for
identifying novel bacterial and endogenous SR-A ligands was
developed (20). In this ELISA-based assay, lysate from bone
marrow-derived macrophages from WT and SR-A
-/- mice is
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used in combination with a monoclonal anti-SR-A antibody to
detect receptor-ligand interactions. This allowed an extensive
and rapid screen of individual chromatography fractions. In
addition, SR-A is mostly intracellular (21), rendering binding
studies with whole cellssuboptimal, whilelysis increases receptor
availability by releasing this intracellular receptor pool. Since
human, murine, bovine, and rabbit SR-A share a high degree of
homology and similar ligand affinities, SR-A from any available
species can be used to screen human plasma (22). In particular,
the basic residues in the collagenous domain responsible
for ligand binding are conserved between human and murine
SR-A (9). Our results represent a successful application of this
novel ligand identification strategy. We propose that apolipo-
proteins A-I and E are novel ligands for SR-A, bind to the
receptor via the known polyanion binding site, and, when
immobilized, contribute to SR-A-mediated macrophage adhe-
sion. This may have consequences for local macrophage-driven
microinflammation at sites of apolipoprotein deposition, such as
atherosclerotic lesions or Alzheimer’s disease plaques.
EXPERIMENTAL PROCEDURES
Reagents. Human pooled outdated citrated plasma was
obtained from HD Supplies (Aylesbury, U.K.). Recombinant
human apo E and apo SAA were from Peprotech (London,
U.K.), and purified human apo A-I and apo A-II were from
Calbiochem (Nottingham, U.K.). MalBSA was prepared by
reacting BSA with maleic anhydride (23). Fully oxidized LDL
(oxLDL) was obtained by overnight incubation of freshly pre-
pared LDL (1 mg/mL) with 5 μMC u S O 4. To stop the reaction,
100 μME D T Aa n d2 0μM butylated hydroxytoluene (BHT)
were added, and the extent of oxidation was controlled by
SDS-PAGE. Chromatography size calibration standards were
bovine IgG, factor B, and complement factor H (MRC Immu-
nochemistry Unit) and BSA and soybean trypsin inhibitor
(Sigma). Primary antibodies were the monoclonal anti-murine
SR-Aantibody(clone2F8) (Serotec,Oxford,U.K.),monoclonal
rat anti-CD52 (Campath, kindly provided by H. Waldman,
Sir William Dunn School of Pathology) as an isotype control
for anti-murine SR-A, and the sheep polyclonal anti-human apo
A-I antibody (AH213) from Serotec; for secondary antibodies,
HRP-coupled goat anti-rat and donkey anti-sheep polyclonal
antibodies from Jackson laboratories (Stratech, Suffolk, U.K.)
were used.
Preparation of Cell Lysates. Confluent monolayers of
murine bone marrow-derived macrophages (BMMj)f r o m
129/ICR WT and SR-A
-/- mice were washed four times in
PBS, placed on ice, and incubated with 1.5 mL of NP-40 lysis
buffer[150mMNaCl,10mMEDTA,10mMNaN3,10mMTris
(pH 8.0), 1 mM PMSF, 5 mM iodoacetamide, and 1% Nonidet
P-40] per dish. Cells were mechanically detached and lysates
collected,pooled,andclearedofnuclearandcelldebris.Afterthe
determination of the protein concentration by the BCA assay
(Pierce, Perbio Science), postnuclear cell lysates were frozen and
stored at -20 C.
ELISA and Competition ELISA. An ELISA-based assay
for the detection of scavenger receptor ligands using BMMj
lysates is described elsewhere (20). Briefly, High Bind EIA/RIA
96-wellplates(Costar)werecoatedovernightat4Cwithplasma
fractions (in the respective chromatography elution buffer, up to
125 μg of protein per well) or purified ligands (positive control,
MalBSAoracLDL;negativecontrol,BSA,allcoatedat5μg/mL
in PBS), blocked with PBS, 10 mg/mL BSA, and 5 mM EDTA
(blocking buffer), and overlaid with either WT or SR-A
-/-
BMMj lysate (∼60 μg of protein/mL) in blocking buffer. For
competition studies, lysates were preincubated for 1.5 h at RT
with excess concentrations of competitors before addition to
wells.BoundSR-Awasdetectedbyincubationfor1hatRTwith
the rat anti-mouse SR-A monoclonal antibody at 10 μg/mL or
isotype-matched control antibody, followed by incubation for
45 min with HRP-coupled goat anti-rat polyclonal antibody at a
dilution of 1:2000. All antibodies werediluted in blocking buffer.
After color had developed for 5 min, plates were read at 450 nm.
If required, SR-A
-/- OD450 values were subtracted from WT
OD450 values to yield SR-A-specific binding and normalized to
theinternalpositivecontrolforinterassaycomparability(binding
expressed as a percentage of the positive control). For the apo
A-I ELISA, plates were coated and blocked as described above
and then incubated at RT for 1 h with the sheep polyclonal anti-
human apo A-I antibody at a dilution of 1:40000, followed by a
45 min incubation at RT with the HRP-coupled donkey anti-
sheep polyclonal antibody at a dilution of 1:2000. Detection was
conducted as described above.
SDS-PAGE and Far-Western Blot. Proteins were sepa-
ratedonSDS-PAGEgelsinTris-glycinerunningbuffer(24)and
either stained with Coomassie Blue or transferred to HybondC
nitrocellulose (GE Healthcare). Blots were blocked overnight in
blocking buffer (PBS and 4% dried milk powder) and incubated
for 1.5 h at RT with WT or SR-A
-/- BMMj lysate at a level of
0.6 mg of cell protein/mL in blotting buffer (PBS, 4% dried milk
powder,and5mMEDTA).Todetectboundreceptor,blotswere
washedfor 3   5 min withwashing buffer(PBS and 0.1% Tween
20),incubatedfor1.5hatRTwiththeprimaryantibody(sameas
ELISA) at 10 μg/mL in blotting buffer, washed for 3   5m i ni n
washing buffer, and incubated for 45 min at RT with the
secondary antibody (same as ELISA) in blotting buffer. Finally,
blots were washed for 3   5 min in washing buffer, developed
using the enhanced chemiluminescence kit (ECLplus, GE
Healthcare), and visualized on Kodak film. For sequential
detection with different antibodies, membranes were stripped
with Restore Western Blot Stripping Buffer (Pierce, Perbio
Science) according to the manufacturer’s instructions.
In-Gel Tryptic Digest and Mass Spectrometry. Coomassie
blue-stained bands of interest were cut out, diced, and trans-
ferred to low-adhesion grade Eppendorf tubes (Eppendorf,
Cambridge, U.K.). Gel pieces were washed twice for 20 min in
100μLof100mMammoniumbicarbonateand50%acetonitrile,
washed once for 10 min in 100 μL of 100% acetonitrile, then air-
dried for 10 min and covered with ∼25 μLo fs e q u e n c i n gg r a d e
modified trypsin solution (Promega) at 50 μg/mL in 25 mM
ammonium bicarbonate, and incubated overnight at 37 C. To
stop the digest, formic acid was added to a final concentration of
2.5%, and the solution was transferred to a new tube. For
extraction of peptides from the gel pieces, 100 μL of 50%
acetonitrile in water was added for 1 h at RT, transferred
to a new tube, and replaced with 100% acetonitrile for an
additional 1 h at RT. Peptide-containing supernatant was
collected again, and the collected peptides were dried down by
vacuum centrifugation. Mass spectrometry was conducted on a
Waters Q-TOF micro mass spectrometer (Waters, Manchester,
U.K.) coupled to a CapLC device. The reference database
used for mass spectrometric identification of candidate ligands
was MSDB (Mass Spectrometry protein sequence DataBase,
www.matrixscience.com), searching for human entries only.11860 Biochemistry, Vol. 48, No. 50, 2009 Neyen et al.
Acceptance criteria forproteinhits weresetasa minimumoftwo
uniquepeptidesperproteinandaprobability-basedMowsescore
of >45, where Mowse stands for Molecular Weight Search and
allows assignment of a probability to each identified peptide of a
given MW (25).
Chromatography. All chromatography runswereconducted
on € AKTA FPLC apparatus operated by Pharmacia Unicorn
software. Ion exchange was conducted on a MonoQ HR 5/5
column or on a QSepharose High Resolution 16/10 Fast Flow
column equilibrated in running buffer (10 mM Na2HPO4 and
15 mM NaCl, adjusted to pH 7.4). Fresh plasma was cleared
of chylomicrons and precipitates by a 40 min centrifugation at
15000 rpm and 4 C in a Beckman J2-HS centrifuge with a JA20
rotor, filtered through a 0.22 μm filter (Pall, VWR), and diluted
∼1:1 in running buffer before injection. Unbound material was
washed off with running buffer, and bound material was eluted
with a two-stage linear gradient of high-salt buffer (buffer B) [10
mM Na2HPO4 and 1 M NaCl (pH 7.4)] at a flow rate of 1 mL/
min, and 1 mL fractions were collected. The gradient stages (for
the MonoQ column) included a slow increase from 0 to 40%
buffer B (20 mL) and then a steep increase from 40 to 100% B
(5 mL), with a plateau at 100% B (2 mL) and re-equilibration to
0% B. Size exclusion was conducted on a Superose12 HR 10/30
column(ligandfractionation)orontwocoupledSuperose610/30
columns (lipoprotein fractionation) equilibrated in running buf-
fer[PBSand0.5mMEDTA(pH7.4)].Sampleswereinjectedand
elutedwith1.2columnvolumesofrunningbufferataflowrateof
1 mL/min. Fractions (1 mL) were collected throughout the run.
Proteinsofknownsize[bovineIgG(156kDa),factorB(90kDa),
BSA (67 kDa), soybean trypsin inhibitor (21 kDa), and comple-
ment factor H (155 kDa)] were run separately to calibrate the
column. For concentration of samples between chromatography
runs, pooled fractions were centrifuged on Vivaspin 6 mL
concentrators with a 30 kDa cutoff (Vivascience, VWR) accord-
ing to the manufacturer’s instructions.
Depletion of Immunoglobulins and Albumin. Plasma was
depleted of immunoglobulins on a fast flow protein G Sepharose
column (GammaBind Plus Sepharose, GE Healthcare). Five
milliliters of plasma was processed per run. Plasma was passed
through the column with running buffer [PBS and 0.5 mM
EDTA (pH 7.4)], and bound IgG was eluted with 0.2 M glycine-
HCl at pH2.2. The column was regenerated withrunningbuffer.
For albumin depletion, affinity-purified polyclonal rabbit anti-
human serum albumin antibodies (MRC Immunochemistry
Unit) were coupled to CNBr-activated Sepharose (Pharmacia,
GE Healthcare) (26), to a final column capacity of 1 mg of
albumin/mL of bed volume. The column (bed volume of 15 mL)
was equilibrated in 1 column volume (CV) of running buffer
(PBS and0.5mMEDTA), andthen plasma was loadedata flow
rate of 1 CV/30 min, equivalent to 1 mL/2 min, and washed
through with 1 CV of running buffer. Bound albumin was eluted
with1CVofwater,followedby2CVof3MMgCl2(pH6.8)and
1 CV of water. The column was re-equilibrated with 1 CV of
running buffer. All runs were conducted at 4 C.
Isolation of Total Plasma Lipoproteins (27). Ultracen-
trifugations were conducted in a Beckman L8-80M ultracentri-
fuge, using a VTi80 vertical rotor (Beckman) and QuickSeal
polyallomertubeswithacapacityof5.1mL(Beckman).Fortotal
lipoprotein preparation, the density of plasma (d = 1.006 g/mL)
adjusted to 10 mM EDTA and 1 mM PMSF (protease inhibitor)
was increased to 1.21 g/mL with solid KBr, and the mixture was
centrifuged at 4 C for 11.5 h at 55000 rpm. The top fraction
containing total lipoproteins was recovered using a 19-gauge
needle, dialyzed extensively against 150 mM NaCl and 0.5 mM
sodium EDTA (pH 7.4), and stored at 4 C. For size separation
of total lipoproteins, preparations were processed within a week.
Delipidation of Plasma. PHM-L LIPOSORB resin
(Calbiochem) was used to delipidate plasma, according to the
batch procedure of the manufacturer’s instructions. Twenty
milliliters of plasma was mixed with 15 mL of resin by vortexing
for 1 min, and then the resin was pelleted by centrifugation at
3000rpmfor10min.Thelipid-freesupernatantwaskept,andthe
resin was resuspended in 30 mL of PBS for washing. Bound lipid
materialwaseluted whenthe resin wasmixedoncewith35mL of
200 mM sodium deoxycholate and once with 35 mL of 100 mM
NaOH. Eluted material was dialyzed against PBS (pH 7.4).
Adhesion Assay. RAW 264.7 cells were grown in DMEM
supplementedwith10%fetalbovineserum,10mMHepes,2mM
glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin
(all from Gibco/Invitrogen Corp.) and subcultured in bacterio-
logic plastic dishes for at least 24 h before an adhesion assay, to
allow detachment with 5 mM EDTA alone; 96-well flat bottom
tissue culture plates were coated with 30 μL of 2% (w/v) gelatin
containing ligands at the indicated concentrations and left to dry
at 37 C. Cells were washed three times with PBS and then
resuspended at a density of 3   10
6 cells/mL in DMEM and 1%
BSA. Inhibitors were prepared in DMEM and 1% BSA as
follows: 10 mM EDTA, 10 μg/mL rat anti-mouse SR-A mono-
clonal antibody, or a combination of both. For studies with apo
A-I mimetic peptide 4F, the anti-SR-A antibodywas replaced by
4F or control scrambled peptide scr4F at the indicated concen-
trations; 100 μL of inhibitors or medium alone was dispensed to
the ligand-coated wells, followed by 100 μL of cell suspension.
Plates were incubated at 4 C for 30 min to allow binding of
antibodies and then shifted to 37 C for 1.5-2 h to let the cells
adhere. We washed plates carefully by dispensing PBS into the
wells and aspirating washes with a multichannel pipet. Adherent
cells were fixed by incubation with ice-cold methanol for 20 min
at 4 C and then stained with a crystal violet solution. The stain
was solubilized in 100 μL of 1% SDS per well and absorbance
read on a plate reader at 550 nm.
Three-Dimensional Modeling. To generate a three-dimen-
sional model of the collagenous and SRCR domains of human
SR-AI (hSR-AI), the sequence of residues 273-341 (collagenous
domain) of hSR-A (UniProt entry P21757) was entered into the
FFASserver(28)searchingagainstthePDB(ProteinDataBank)
as of September 2007, and PDB entry 1y0f (type I collagen) was
usedasastartingmodelforthecollagenousdomain(structureby
fiber diffraction; CR atoms only). The human SR-A sequence
was docked onto the CR positions of the collagen structure using
the SCWRL server (29), and main and side chain atoms were
further modeled using MODELLER (30). The SRCR of SR-A
(residues 350-450) was modeled onto the trimeric SRCR of
MARCO, for which a crystal structure is known (PDB entry
2oya, using the AB dimer in the asymmetric unit and copy B in
cell x-1,y,z). The model for hSR-AI was built in MODELLER
by combining the model of the trimeric head of MARCO
described above and the collagen 1 trimer.
The model hSR-AI structure and either the human apo A-I
structure (PDB entry 2a01) or the human apo E structure (PDB
entry 1ea8) were docked together using the suite of Haddock
scripts (31), with constraints on docking residues of SR-A as
follows: Arg325, Lys332, Lys335, and Lys338. After water
refinement,thelowest-energypairsof200structureswerechosen.Article Biochemistry, Vol. 48, No. 50, 2009 11861
The MSDPisa server (32) was used to determine contact residues
and interaction characteristics.
Data Analysis. All data presented were analyzed using
GraphPad Prism, version 5.0 (GraphPad Software, San Diego,
CA). Unless otherwise indicated, data are shown as means of
triplicates with the standard deviation (SD). For comparison of
grouped variables (ELISA, adhesion), two-way ANOVA with
Bonferroni postcomparison tests were used to determine signifi-
cance. One asterisk indicates P < 0.05; two asterisks indicate
P < 0.01 and three asterisks P < 0.001.
RESULTS
PurificationofSR-ACandidateLigandsfromPlasma.A
combination of chromatographic separation techniques and
an ELISA-based SR-A binding screen (20) paralleled by far-
Western blot was used to identify candidate SR-A ligands from
human plasma (see Figure 1 of the Supporting Information for
details of the workflow). Although serum and plasma exhibit
comparable ligand activity (data not shown), plasma was used
for fractionation to prevent unwanted modifications induced by
the proteases activated during the clotting cascade. Since all
known SR-A ligands are polyanions, the complexity of the
plasma was first reduced by anion exchange, followed by an
ELISAscreenwithlysatesfromWTandSR-A
-/-BMMjonthe
eluted fractions. The resulting two-peak SR-A binding pattern is
shown in Figure 1A. Ligand detection was selective for specific
proteins as the SR-A binding trace did not simply reflect the
protein elution profile. The two specific ligand peaks eluted at
∼300 mM NaCl (30% high-salt buffer) and after 1 M salt had
been reached, suggesting either a very highly charged ligand or
one that interacts with the column resin. Unbound material
eluting before the salt gradient gave an equal signal in the
presence and absence of detecting SR-A in ELISA (Figure 2A
oftheSupportingInformation). Thesamewasobservedwhenan
isotype control antibody instead of anti-SR-A was used (Figure
2B of the Supporting Information), but not when IgG-depleted
plasma was fractionated, demonstrating that this signal was due
to cross-reaction of the secondary antibody with immunoglobu-
lins and not to specific SR-A ligands in these neutral or basic
fractions. To remove nonspecific background from subsequent
screens, either plasma was cleared of IgG prior to fractionation
[which did not affect the two-peak SR-A binding pattern
(Figure1A)]orbindingwasexpressedastheSR-A-specificsignal
(WT minus SR-A
-/-). To allow interassay comparability, this
value was normalized to an internal positive control (known
SR-A ligand).
While the first peak had a clearly detectable absorbance at
280 nm, suggesting a protein ligand, the second peak did not
contain any detectable material at this wavelength, impeding
furtheranalysiswithconventionalproteinbiochemistrymethods.
Therefore, only ligand-containing fractions 30-35 (peak 1) from
plasma and IgG-depleted plasma ion exchange were pooled,
affinity-depleted of albumin, concentrated, and further fractio-
nated by size exclusion on Superose12 (fractionation range up to
FIGURE 1: Identification of novel endogenous SR-A ligands in human plasma. (A) One milliliter plasma devoid of precipitates and
chylomicrons or 3.5 mL of the same plasma depleted of immunoglobulins was diluted with running buffer to a total volume of 5 mL,
injected onto a MonoQ High Resolution 5/5 column, and eluted with a two-stage salt gradient from 0 to 1 M NaCl. Fractions (1 mL) were
collected and assayed via an ELISA for SR-A binding activity as described in Experimental Procedures. The FPLC elution profile
with absorbance at 280 nm (line) and conductance (millisiemens per centimeter) indicating salt strength (dotted line) is shown along with
SR-A-specificbinding (b), wherespecificbindingiscalculatedasWTminus SR-A
-/-. Arrowsindicatepeaks ofSR-Abinding;thebar indicates
fractionspooledforfurtherfractionation.(B)Onemilliliterofconcentratedalbumin-depletedactivepool(fractions30-35frompanelA,plasma,
and IgG-depleted plasma) was injected onto a Superose12 HR 10/30 column. Fractions (1 mL) were collected and assessed for SR-A binding
activity in ELISA (fractions 6-16). Binding (b), expressed as the percentage of binding to the internal positive control (5 μg/mL acLDL), is
plotted vs absorbance (333). (C) Ten microliters offractions 9-13was boiled in nonreducing loading buffer, subjected to8% SDS-PAGE, and
either stained with Coomassie blue or transferred to a nitrocellulose membrane and subjected to far-Western analysis, using WT and SR-A
-/-
BMMj lysates as described in Experimental Procedures. The strongest SR-A binding areas are indicated by boxes (around 160, 75-35, and
25 kDa).11862 Biochemistry, Vol. 48, No. 50, 2009 Neyen et al.
approximately 300 kDa). Albumin depletion had no notable
effect on SR-A reactivity, and the discarded albumin-enriched
material showed no significant SR-A binding activity (not
shown). Albumin-free material eluted in two contiguous peaks,
with SR-A reactivity localizing to the second peak only
(Figure 1B). A parallel chromatography with molecular mass
standardsallowedtheligand-containingpeak(fractions9-12)to
be centered on 160 kDa. However, the activity peak was quite
broad, suggesting that the ligand might not be homogeneous.
Nonreducing SDS-PAGE andfar-Westernanalysis (Figure1C)
of the corresponding fractions revealed several areas of SR-A
reactivity, corresponding to apparent molecular masses of
approximately 160, 75-35, and 25 kDa, suggestive of a ligand
that would form a protein complex or aggregate in solution
but (partially) dissociate into monomers under denaturing
conditions.
Identification of Candidate Ligands by Mass Spectro-
metry. Four strong SR-A-reactive bands from fractions 9 and
10, at apparent molecular masses of <75, >50, 35, and 25 kDa
(Figure 1C), were excised and subjected to in-gel tryptic digest,
and peptides were analyzed by electrospray mass spectrometry.
The first candidate list (Table 1 of the Supporting Information,
first run) included a large number of complement breakdown
products (C3), protease inhibitors (inter-R-trypsin inhibitor,
C1 inhibitor), and numerous hits of apolipoprotein A-I. To
increase the reliability of mass spectrometry hits, the described
ligand purification (ion exchange, size exclusion) was repeated at
a larger scale and seven putative SR-A-reactive bands were
excised and subjected to mass spectrometry. The second candi-
date list (Table 1 of the Supporting Information, second run)
confirmed initial hits and made it possible to select complement
C3 (C3) and apolipoprotein A-I (apo A-I) as the two most
promising candidate ligands. While both C3 and apo A-I were
foundinall four bandsofthe first run, C3scored better thanapo
A-I (average scores of 558 and 211, respectively) and was
identified by a higher average number of unique peptides
(12 and 3.75, respectively). However, average sequence coverage
was higher for apo A-I (16.25%) than for C3 (8%). As both the
number of unique peptides and sequence coverage are somewhat
dependent on the length of the protein, score was considered the
most reliable rating criterion.
Ina manner independent of score, however,several considera-
tions arguedinfavorof apoA-Ibeing the maincandidateligand.
Since the constitutive low level of complement activation in
plasma leads to covalent association of C3 with random plasma
proteins, it is highly likely to find complement components in
mass spectrometry searches. Similarly, high-abundance plasma
proteins (albumin, immunoglobulins, antitrypsin, transferrin,
and haptoglobin) are known to interfere with mass spectrometry
sensitivity because they mask minor components. Apo A-I is the
main protein constituent of high-density lipoprotein (HDL),
which spans a size range from 155 to 416 kDa in healthy
subjects (33). This agrees with the apparent molecular mass of
the SR-A ligand determined by size exclusion chromatography
(160 kDa). In addition, most table entries belonged to functional
classes (proteinase inhibition, complement regulation, acute
phase response, and lipid metabolism) recently found to be
associated with HDL by shotgun proteomics (34). Therefore,
apo A-I was retained as the main SR-A candidate ligand.
Novel SR-A Ligands Are Derived from HDL. To test
whether the identified SR-A-reactive compound was
carried on HDL, total plasma lipoproteins were isolated by
ultracentrifugation, subjectedt os i z ee x c l u s i o nc h r o m a t o -
graphy, and assessed for SR-A reactivity via an ELISA
(Figure 2A). Consistent with SR-A recognition of modified
LDL, which occurs at basal levels in plasma, the LDL peak
showed weak SR-A binding. Astonishingly, the HDL peak
bound SR-A strongly, contradicting the established convic-
tion that HDL is not an SR-A ligand. However, oxidation of
HDL by plasma enzymes such as myeloperoxidase is a
physiologically occurring modification and has been shown
to target HDL to various scavenger receptors, including SR-
A( 35). Oxidation results in a ladderlike running pattern of
HDL proteins on gels, mainly due to covalent aggregation of
apo A-I and/or apo A-II. When HDL fractions were tested
for SR-A reactivity by far-Western blot (Figure 2B), the
observed banding pattern was similar to that in Figure 1C,
with SR-A-reactive bands at <75, 50, and 25 kDa. A parallel
apo A-I Western blot proved the presence of apo A-I in
four different bands, at <75, 50, <35, and 25 kDa (filled
arrowheads, Figure 2B). Note that the relative intensities of
SR-A- and anti-apo A-I antibody-dependent recognition
of higher-order apo A-I aggregates differ, suggesting pre-
ferential recognition of aggregated material by SR-A. The
additional SR-A-reactive band at 14 kDa (empty arrowhead,
Figure 2B) was not identified on the apo A-I blot and might
FIGURE 2: Distribution of SR-A binding activity in plasma lipopro-
teins. (A) One milliliter of total plasma lipoproteins from a single
donor was isolated by ultracentrifugation at a density of 1.25 g/mL
and separated bysizeexclusion chromatography via FPLC(---),and
fractions were analyzed for SR-A reactivity (b). Data are represen-
tative of three different donor profiles. (B) The HDL peak fractions
(28-30) were separated by nonreducing 6 to 20% SDS-PAGE,
transferred to a blotting membrane, and detected in the following
order: far-Western blot with SR-A-containing cell lysate and isotype
control, stripped for 15 min, far-Western blot with SR-A-containing
lysateandanti-SR-Aantibody,strippedfor10min,andWesternblot
with anti-apo A-I antibody. Filled arrowheads indicate apo A-I
bands at <75, 50, <35, and 25 kDa, and the empty arrowhead
indicates the non-apo A-I, SR-A-reactive band at 14.3 kDa. Bands
above 105 kDa on far-Western blots are due to cross-reacting
secondary antibody.Article Biochemistry, Vol. 48, No. 50, 2009 11863
correspond to apo A-II, the second-most abundant apolipo-
p r o t e i no fH D La n ds t r u c t u r a l l ys i m i l a rt oa p oA - I( 36).
These findings point toward recognition of oxidized or
aggregated rather than native apo A-I. To verify whether
signatures of enzymatic oxidation could be found among the
apo A-I peptides identified by mass spectrometry in our
study, we reanalyzed all peptides with search criteria modi-
fied to include oxidative modifications. Myeloperoxidase
specifically oxidizes selected methionine and tyrosine resi-
dues of apo A-I, including Met86 (37), which was indeed
identified on several distinct peptides.
PlasmaContainsLipid-AssociatedandLipid-FreeSR-A
Ligands. To remove all lipid-associated SR-A ligands from
plasma and test for remaining SR-A reactivity, plasma was
delipidated using a lipophilic resin. Both the lipid-free plasma
and the apolipoprotein-enriched eluates from the resin were then
subjected to SDS-PAGE and far-Western blot (Figure 3A). On
SDS-PAGE (Figure 3A, left panel), note the absence of strong
bands in the apo A-I size region (25-30 kDa) in delipidated
plasma and the resin wash, and corresponding strong bands in
eluates, indicating efficient removal of apo A-I by the delipida-
tion step and enrichment on the resin. On the far-Western blot
(Figure 3A, right panel), four size areas reacted with SR-A,
among which bands above 105 kDa were seen on both WT
and SR-A
-/- overlays, corresponding to cross-reaction of the
secondary antibody with plasma immunoglobulins. A strong
SR-A-specific band around 67 kDa (similar in size to the control
SR-A ligand MalBSA) potentially corresponds to some form of
modified albumin, as it is abundantly present in plasma and
was unaffected by delipidation. Indeed, AGE-modified albumin
FIGURE 3: Plasma contains lipid-associated and lipid-free SR-A binding activity. (A) Plasma (20 mL) was delipidated on 15 mL of PMH-L
Liposorb resin slurry as described by the manufacturer. Eluates with sodium deoxycholate (eluate 1) and sodium hydroxide (eluate 2) were
dialyzedagainstPBSandadjustedtothestartingvolume.Aliquotsofdelipidationsteps(plasma,P;delipidatedplasma,DP;PBSwash,w;eluates
predialysise1,e2;eluatespostdialysisE1,E2)wererunonanonreducing6to20%SDS-PAGEgradient,alongwith5μgofpositiveandnegative
controls(MalBSA,MB;BSA, B)per laneand 5 μgofpurified apo A-I(AI) per lane.Identicalgelswereblotted onnitrocellulosefor far-Western
blotswithWTandSR-A
-/-lysates.TheblackarrowheadontheSDS-PAGEgelindicatesthepositionofapoA-I,andwhitearrowheadsonthe
blot indicate SR-A ligands in plasma, corresponding to proteins with apparent molecular masses of >25, >35, and ∼67 kDa. (B) One milliliter
eachoftotalplasmaandLiposorb-delipidatedplasmawerefractionatedonaQSepharosecolumn[elutionprofilebyabsorbanceat280nm(333)],
andeverysecond1mLfractionwastestedforSR-Areactivity(b)andapoA-Icontent(;)viaanELISA.Zone1indicatesdelipidation-sensitive
and zone 2 delipidation-resistant SR-A binding activity.11864 Biochemistry, Vol. 48, No. 50, 2009 Neyen et al.
occurs at low levels even in non-diabetic patients and has
been proven to be a ligand for SR-A (38). Two lipid-associated
SR-A-specific bands localized above 35 kDa (the size of apo E)
andbelow30kDa,thelatterlikelycorrespondingtoapoA-I.The
far-Western assay used in this work may detect only ligands that
are resistant to denaturation or that may renature at least
partially on blotting. The ELISA, however, does not involve
ligand denaturation and so might detect additional ligands that
are more fragile. Therefore, delipidated plasma was fractionated
by ion exchange, and all fractions were screened for the presence
ofapoA-IandSR-AreactivityviaanELISA(Figure3B,bottom
panel). Fractionation of delipidated plasma was compared to an
identical fractionation of total plasma (Figure 3B, top panel). As
in Figure 1A, ion exchange fractionation of plasma yielded two
separate zones of SR-A binding activity, and again the second
zone had very weak absorbance at 280 nm and eluted at a high
salt strength. In plasma fractions, both zones contained apo A-I,
with close overlap betweenSR-Abinding andapo A-I content in
zone 1. In delipidated plasma fractions, the SR-A-reactive, apo
A-I-containing zone 1 was absent, confirming the hypothesis of
lipid-associated apo A-I as a major SR-A ligand. However,
binding and apo A-I traces in zone 2 were unaffected by
delipidation, suggesting that zone 2 corresponds to small
amounts of intact or fragmented lipid-free apo A-I and poten-
tially additional ligands. Filtration on centrifugal columns with
different molecular mass cutoffs showed that ligand activity in
zone 2 was associated with a molecular entity above 10 kDa.
Traces of apo A-I could be proven by Western blot, and
SDS-PAGE showed additional bands between 10 and 14 kDa
potentiallycorrespondingtoapoA-II(notshown).Similartothe
oxidative hypothesis raised above, thissuggested that fragmenta-
tion and/or aggregation generates SR-A ligands from apo A-I.
FIGURE 4: ApoA-IandapoEisoformsarenovelligandsforSR-A.(A)RecombinanthumanapoE2,E3,E4,andSAA andpurifiedhumanapo
A-I(allat500nM),purifiedHDL(250nM),andcontrolligandsMalBSA(positive)andBSA(negative) (150nM) werecoatedonELISAplates,
and SR-A reactivitywas detected bycomparison ofWT(black bars) and SR-A
-/- (white bars) lysates asdescribed inExperimental Procedures.
ThreeasterisksindicateP<0.001forWTvsSR-A
-/-comparedbytwo-wayANOVAandBonferronipost-tests.Resultsarerepresentativeofat
least three similar experiments. (B) Five micrograms of control ligands MalBSA (positive) and BSA (negative) or candidate ligands apo E2, E3,
E4, and apo SAA and HDL containing apo A-I and apo A-II were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and
assessedforSR-Areactivitybyfar-WesternblotasdescribedinExperimentalProcedures.LocalizationofproteinswasvisualizedbyPonceauRed
stainingofthe membrane prior tofar-Western blot. (C) Apo A-I (250 nM) and apo E isoforms(125 nM) (total volume of50μL) were coatedon
ELISA plates and detected with WT or SR-A
-/- lysates as described. For competition, lysates were preincubated with acLDL or oxLDL at a
concentration of 50 μg of apolipoprotein/mL for 30 min at RT. Results are expressed as the percentage of residual SR-A-specific binding. One
asterisk indicates P < 0.05, and three asterisks indicate P < 0.001 for competitor vsunblocked compared bytwo-way ANOVA and Bonferroni
post-tests.Article Biochemistry, Vol. 48, No. 50, 2009 11865
Confirmation of Novel SR-A Ligands. Ligand identifica-
tion so far suggested apo A-I and potentially also apo A-II and
apo E as novel SR-A ligands. Further, receptor binding seemed
to be induced or enhanced by oxidative modifications, aggrega-
tion or degradation. To test whether native apolipoproteins are
novel ligands for SR-A and to prove specificity for select
apolipoproteins,variouspurifiedhumanapolipoproteins,includ-
ing apo A-I and A-II, all three human apo E isoforms (E2, E3,
and E4), and serum amyloid A (apo SAA), which replaces apo
A-I in HDL during the acute phase response, were tested for
SR-Areactivity. When WTwas compared tothe SR-A
-/- signal
via an ELISA (Figure 4A), significant binding was detected for
apo A-I, HDL (containing both apo A-I and apo A-II), and all
apo E isoforms, but not apo SAA. Comparison of WT and
SR-A
-/- far-Western blots (Figure 4B) confirmed this recogni-
tion pattern, with a strong SR-A-specific signal for all apo
E isoforms and apo A-I, but not for apo A-II or monomeric
apo SAA. The band above 50 kDa in the apo SAA lane most
likely corresponds to aggregated or multimeric apo SAA, in
agreement with known SR-A recognition of amyloid aggre-
gates (39). An additional proof of receptor specificity is the
abilitytocompetewithestablishedligands.Therefore,theELISA
was repeated in the presence of competitors. OxLDL and, to
some extent, acLDL blocked recognition of all novel SR-A
ligands (Figure 4C), suggesting that the novel ligands share the
same receptor binding site as known ligands. Taken together,
these experiments suggested that SR-A recognition of
apolipoproteins is lipid-independent and selective and
does not seem to depend on oxidative modification. However,
both ELISA and far-Western blot assays depend on immo-
bilization or unfolding of the protein ligand and do not
prove that native, soluble proteins will interact with the
receptor.
This study set off with the hypothesis that plasma contains
endogenous ligands capable of mediating SR-A-dependent
macrophage adhesion. Therefore, the novel candidate ligands
weretestedinanSR-A-specificadhesionassay.First,adhesionof
RAW 264.7 macrophages was assessed on a matrix of gelatin,
which doesnotsustainSR-A-dependentadhesion, or on a mixof
gelatin matrix and plasma or HDL (Figure 5A). In the latter
setting, macrophage adhesion is expected to occur through
integrins, which can be inhibited by divalent metal ion chelation
with EDTA, and through SR-A, which can be abolished by a
monoclonal blocking antibody against SR-A, while a combina-
tion of both completely abrogates adhesion (16). Macrophages
adhered to plasma and HDL in an SR-A-dependent manner,
proving that plasma contains an adhesion ligand that copurifies
with HDL. Next, protein candidate ligands apo A-I and apo
E were tested for their capacity to mediate SR-A-specific macro-
phage adhesion. Apo A-I is found in atherosclerotic vascular
plaques and apo E in neurodegenerative lesions of Alzheimer’s
disease, both macrophage-driven chronic inflammatory patho-
logies characterized by amyloid-associated deposits of dena-
tured, unfolded, or truncated proteins (40-42). Among the apo
Eisoforms,apoE4wasdeemedthemostphysiologicallyrelevant
since the APOE4 allele is associated with late-onset Alzheimer’s
disease (43). Integrin-independent adhesion of macrophages to
immobilized apo A-I or apo E4 was dose-dependent, completely
blocked by anti-SR-A antibodies, and specific for the novel
ligands, since no adhesion was observed with gelatin and BSA
(Figure5B).AlthoughRAW264.7macrophagessecreteapoEat
aratecomparabletothatofimmaturemonocytes(44),thelackof
adhesion to BSA-coated wells proved this endogenous apo E did
not contribute to adhesion in our assay. To exclude any additive
effectsfrom nonquantified endogenous apo E infuturestudies,it
wouldbeofexperimentalbenefittouseJ774macrophages,which
do not express apo E.
The Shared Amphipathic R-Helix of Apo A-I and Apo E
IsaMinimalBindingMotifforSR-A.Allknownpolyanionic
SR-A ligands interact with a stretch of positively charged lysines
within the receptor’s collagenous ligand binding domain (9, 45).
CompetitionbetweenknownSR-Aligands(acLDLandoxLDL)
and the novel ligands identified here (Figure 4C) already
established that both groups likely bound to overlapping or
identical sites on the receptor. It would thus seem plausible
that recognition relied on interaction between positive receptor
residues and negative ligand residues, either present in the native
stateorinducedbymodification.Sincepurifiedandrecombinant
apolipoproteins were able to bind the receptor (Figure 4A,B),
modification did not seem an absolute prerequisite, and native
negative charge was favored as a hypothesis. Apo A-I and apo
E belong to an evolutionarily conserved family of exchange-
able apolipoproteins, which are characterized by amphipathic
R-helical repeats (46). Superposition of electron density maps of
lipid-free apo A-I and apo E has revealed that both molecules
exhibit a large negative surface, which results from parallel
packaging of R-helices and remains solvent-exposed even after
rearrangement of helices around lipid globules (47). 4F is an
FIGURE 5: Novel SR-A ligands apo A-I and apo E4 mediate macro-
phageadhesion.(A)AdhesionofRAW264.7macrophagestoligand-
coated tissue culture plastic plates [coated with 2% (w/v) gelatin,
nonadhesive negative control; plasma 1:10 or HDL at a concentra-
tion of 50 μg of apolipoprotein/mL diluted in 2% (w/v) gelatin] was
assessed in the absence of inhibitors or in the presence of mouse
monoclonal anti-SR-A blocking antibody, EDTA (for integrin-
independent adhesion), or a combination of both. Two asterisks
indicate P <0 . 0 1a n dt h r e ea s t e r i s k sP < 0.001 comparing condi-
tions with inhibitors to unblocked control by two-way ANOVA and
Bonferroni post-tests. Results are representative of three similar
experiments. (B) Dose-dependent adhesion of RAW 264.7 macro-
phagestoimmobilizedapoA-IandapoE4wastestedasdescribedfor
panel A. For the sake of clarity, only adhesion in the presence of
EDTA(;)orEDTAandanti-SR-A(333)isshown.BSAwasusedas
a negative control ligand. Results are representative of two similar
experiments.11866 Biochemistry, Vol. 48, No. 50, 2009 Neyen et al.
apo A-I mimetic peptide 18 amino acids in length, which
reproduces the features of apo A-I amphipathic R-helices
based on a hydrophobic, lipid-associating and a negatively
charged, solvent-exposed side without having any sequence
similarity,anddisplaysmanifoldanti-atherogenicandbroadly
anti-inflammatory properties (48-52). If the shared amphi-
pathic R-helix was a minimal binding motif, then 4F should be
able to compete with known and novel SR-A ligands alike,
since both seem to bind the same receptor site. In an ELISA-
based competition assay, soluble 4F, but not a scrambled
control peptide (scr4F), blocked binding of SR-A to known
ligands acLDL and oxLDL, as well as to novel ligands apo
A-I, E2, E3, and E4, while nonligands BSA and apo SAA were
unaffected (Figure 6A). In the whole-cell adhesion assay, the
apo A-I mimetic peptide dose-dependently inhibited integrin-
independent adhesion of RAW 264.7 macrophages to apo A-I
and apo E4 (Figure 6B). We therefore assumed short amphi-
pathic R-helices containing a negatively charged side repre-
sented a minimal binding motif as the basis of selective
apolipoprotein recognition by SR-A.
Proposed Interaction Model of the Collagenous Ligand
Binding Domain from Human SR-A with Apolipoproteins
A-I and E. The data presented above are consistent with an
interaction model in which both newly identified and known
ligands share the same binding site on SR-A. No structure is
available for the complex trimeric transmembrane receptor SR-
A; however, its collagenous ligand binding domain closely
resemblescollagenI,andtheSRCRdomainsofclassAscavenger
receptors SR-A and MARCO are highly conserved, allowing
three-dimensional modeling of the binding and head regions
(Figure 7A, residues involved in binding highlighted in red).
Thethree-dimensionalstructuresofapoA-IandapoEhavebeen
determined at 2.4and 1.95 A ˚ , respectively (PDB entries 2a01 and
1ea8, respectively) and show considerable overlap in structure.
Mostimportantly,whenbundledinalipid-freestate,theypresent
a large solvent-accessible negative patch, which unfolds into
smaller negative stretches upon association with lipid bilayers or
disks (47). The four-helix domain common to both apo A-I and
apo E (Figure 7B), corresponding to amino acids 1-190 of
human apo A-I or amino acids 23-162 of human apo E3, was
used to model the interaction with SR-A, as it contains the
negativeresiduespotentiallyinvolvedinSR-Abinding.Bothapo
A-I and apo E3 helix domains were separately docked with the
model for the SR-A receptor; in both docking calculations, the
only restraint imposed was that one of the known contact
residues on the receptor side would contact the apolipoprotein.
Of 200 possible receptor-ligand pairs in both docking calcula-
tions, the energetically most favorable pairs with maximal
interaction surfaces were selected. All involved the apolipopro-
teindockingtothereceptorbindingdomaininaparallelmanner,
with consecutive negative residues (Asp or Glu) on ligand helices
locking one or more positive residues in the receptor binding
domain (Arg317, Arg325, or Lys338) (Figure 7C, SR-A:apo AI,
and Figure 7D, SR-A:apo E). The energetically most favorable
models used a single helix for interaction, a finding compatible
with lipid-free apolipoprotein (helix bundle), HDL (unfolded
helices), or short lipid-free R-helical peptides binding to SR-A.
Modeling with the murine collagenous receptor domain pro-
duced comparable interactions (not shown). The models are
therefore consistent with the hypothesis of an interaction pair
involving negative residues of a ligand R-helix contacting the
known binding site on SR-A.
FIGURE 6: Identification of a minimal binding motif on novel apolipoprotein ligands. (A) Apo A-I mimetic peptide (4F, sequence




(B) Adhesion of RAW 264.7 macrophages to immobilized apo A-I and apo E4 was tested in the presence of increasing concentrations of 4F or
controlscr4F(singlevalueshown,highestdose),andIC50valuesweredeterminedusinganonlinearregressionmodelwithavariableslope.Error
bars represent the standard error of the mean.Article Biochemistry, Vol. 48, No. 50, 2009 11867
DISCUSSION
Our aim was to investigate SR-A-mediated adhesion by
identifying endogenous ligands in plasma. We propose that
exchangeable apolipoproteins A-I and E represent a novel class
of endogenous SR-A ligands, compete with known ligands
acLDL and oxLDL for the known binding site on the receptor,
and use their shared amphipathic R-helix as a minimal recogni-
tion motif for binding to SR-A. Immobilized apo A-I and apo
E sustain integrin-independent, SR-A-mediated macrophage
adhesion, which may represent a mechanism through which
SR-A contributes to the trapping of macrophages at sites of
pathological apolipoprotein deposition.
Structural Considerations. Exchangeable apolipoproteins
are structurally conserved from insect apolipophorins to
human apolipoproteins (53, 54). Their lipid-free conformation
is based on a helix bundle with hydrophobic domains shielded
from the solvent and a large solvent-exposed negative domain.
During lipid association, the amphipathic helix bundle unfolds
and concatenates its helices to wrap around lipid disks or
globules (47). This implies that SR-A could recognize exchange-
able apolipoproteins via their solvent-exposed negative domains
in both lipid-free (bundled) or lipid-associated (unfolded, con-
catenated) conformations. In addition, recognition of a small
peptide containing as few as four negative residues supports the
concept of a short, robust minimal binding motif, potentially
found in unrelated molecules. However, not all apolipoproteins
tested in this study bound to SR-A. Apo SAA presents only
limited R-helical content; apo A-II, despite its amphipathic
R-helical structure, is considerably shorter than apo A-I or apo
E, and its charge distribution may differ. Interestingly, known
SR-Aligands acLDL and oxLDL differed slightlyin their ability
to compete with the novel ligands (Figure 4C), and reciprocally,
the apo A-I mimetic peptide differentially inhibited SR-A
recognition of acLDL and oxLDL (Figure 6A). While this may
simply reflect the differential receptor binding residue usage
underlying the nonreciprocal cross-competition of oxLDL and
acLDL (9, 55), it could also indicate that exchangeable apolipo-
proteins recapitulate an oxidation-specific epitope present exclu-
sively on oxLDL.
Novel SR-A Ligands Are Derived from High-Density
Lipoprotein. A shotgun proteomics study comparing HDL
from healthy subjects and coronary artery disease patients
FIGURE 7: ProposedmodelofinteractionofhumanSR-AwithapolipoproteinsA-IandE3.(A)Thecollagenousligandbindingdomainofhuman
SR-A, modeled onto the NMR diffraction structure of collagen I (PDB entry 1y0f), and the SRCR domain modeled according to the SRCR of
classAscavengerreceptorMARCO(PDBentry2oya)wereassembledusingMODELLER.Residuesimplicatedinligandbindingarecoloredred
andlabeledforonechainonly.(B) OverlayofapoA-Iresidues1-183(PDBentry2a01,blue) andapoE3residues23-162(PDBentry1ea8,turquoise)
showing the similarity ofthree-dimensional features. (C) SR-A collagenous domain and the first four helices of apo A-I docked together using
Haddock. The inset shows a crucial receptor binding residue, Arg317, clamped between two negative residues on apo A-I, Asp24 and Asp28.
(D) Similar docking with apo E3. The inset shows two conserved receptor binding residues, Arg325 and Lys338, clamped between Asp50 and
Asp59 and between Asp66 and Asp70, respectively. The numbering of apolipoprotein residues corresponds to the mature protein (precursor
numbering = mature protein numbering þ 24 for apo A-I and þ 18 for apo E3).11868 Biochemistry, Vol. 48, No. 50, 2009 Neyen et al.
identified proteins involved in the acute phase response, pro-
teinaseinhibition,andcomplementregulationinadditiontolipid
metabolism (34). Overlapping hits between this and our study
include acute phase proteins kininogen-1 and serum albumin,
protease inhibitors inter-R-trypsin inhibitor heavy chain H4
and R-1-antitrypsin, complement components C3 and C4, and
HDL-associated antioxidant enzyme paraoxonase, validating
the accuracy of mass spectrometry-based identification of candi-
dateligands.ToascertainthatapoA-IwastheonlyHDLprotein
involved in SR-A binding, several high-scoring hits were tested
for binding to SR-A. R-1-antitrypsin and R-1-antichymotrypsin
both tested negative. Complement iC3b is known to promote
macrophage adhesion via complement receptor CR3 (56), a
mechanism that is divalent metal ion-dependent and would thus
not account for the EDTA-resistant adhesion mechanism with
respect to serum-coated surfaces at the base of this study.
Initial receptor binding studies described here involved im-
mobilizationoftheligands,whichmighthaveinducedconforma-
tional changes or aggregation, thereby deriving SR-A ligands
from HDL. It cannot immediately be concluded that apolipo-
proteins are sufficient for receptor interaction with HDL, even
though apo A-I mimetic peptides in solution were able to
compete with known ligands for receptor usage. Rather, SR-A
is defined by its ability to scavenge obsolete material, including
oxidized,denatured,andaggregatedmolecules,andisnotknown
to bind native lipoproteins or HDL in particular. Indeed,
preliminary cell association assays with HDL protected from
oxidation by the addition ofthe antioxidant probucol showed no
difference between WT and SR-A
-/- BMMj,i nl i n ew i t ht h e
lack of detectable HDL phenotype in SR-A
-/- mice. This may
indicate that additional factors, like oxidative modification, are
needed to increase negative charge or that aggregation or
unfolding on surfaces is necessary to confer SR-A binding
capacity to apolipoproteins. In vivo enzymatic oxidation of
HDL specifically targets tyrosine and methionine residues of
apoA-I,whichresultsinimpairedacceptanceofcholesterolfrom
ABCA1 and SR-BI (37). SR-A has been implicated in the
metabolism of myeloperoxidase-modified HDL (35) and may
constitute a scavenging mechanism for the removal of this
nonfunctional entity from the organism. Whether this relies
partially or at all on recognition of apo A-I remains to be
determined.
Similarly, whether SR-A-dependent adhesion to apo A-I and
apo E is a phenomenon of frustrated endocytosis or a distinct
mechanism remains to be investigated. Different cytoplasmic
domains of SR-A are involved in adhesion and receptor inter-
nalization (57), andcellspreading after adhesion has beenshown
to induce distinct signaling pathways from ligand-activated
receptor internalization (58, 59). Bound SR-A ligands usually
undergo receptor-mediated endocytosis followed by lysosomal
delivery (12), but since HDL does not seem to be an endocytic
ligand, it is likely that apolipoprotein recognition willsolely elicit
adhesion pathways.
PathophysiologicalImplicationsandTherapeuticPoten-
tial. Age-related chronic inflammatory pathologies such as
atherosclerosis and Alzheimer’s disease are characterized by
combined accumulation of activated macrophages and micro-
glia, which express high levels of SR-A (60, 61), and pathological
deposition of apolipoproteins. Macrophage adhesion through
scavenger receptors is well-characterized, including binding of
SR-A to extracellular matrix proteins, biglycan and decorin (19),
glycatedcollagenIV(17),andβ-amyloid(39),aswellasadhesion
of CD36 to myeloperoxidase-modified LDL (oxLDL) (62).
Surprisingly, ablation of both receptors in atherosclerosis-prone
apo E
-/- or C57BL/6 mice does not decrease overall lesion area,
suggesting that additional adhesion mechanisms share the re-
sponsibility of lesional macrophage retention (63, 64). However,
engagement of both receptors activates cell responses that
contribute to the progression of disease: engagement of SR-A
or CD36 with immobilized ligands induces a spread morphology
with formation of filopodia and focal adhesion complexes,
through a common signaling pathway (Src nonreceptor protein
tyrosine kinases, MAPK serine/threonine kinases) (65-68), and
blocks macrophage chemotaxis (39, 62, 69, 70), suggesting both
receptors are involved in macrophage accumulation in lesions.
SR-A- and CD36-mediated adhesion to amyloid substrata or
immobilized but not soluble oxLDL induces ROS production in
microglia and macrophages (39, 62, 69, 71), increasing the
oxidative stress on their immediate environment. Our findings
suggestthatthenovelSR-Aligands,whicharefoundasinsoluble
deposits at sites of chronic inflammation, contribute to retention
of macrophages and induce a pro-inflammatory, oxidative state,
which in turn would drive accumulation of pro-atherogenic
oxidized lipoproteins in the arterial wall or induce neurological
damage in the brain. Indeed, several studies have proven the
presence of apo A-I within atherosclerotic lesions (40, 72), along
with apo A-II and apo B (73-75). In many cases, apolipo-
proteins colocalize with extracellular matrix proteoglycans,
many of which are scavenger receptor ligands in their own
right (19, 75, 76). Similarly, senile Alzheimer’s plaques contain
a plethora of apolipoproteins, including apo A-I and apo E (41).
Apo A-I is present throughout all stages of lesion development,
suggesting that SR-A- and apo A-I-dependent macrophage
retention could occur from an early stage of disease. Early
immunohistochemistry studies have shown colocalization of
macrophages with apo A-I and/or apo E in human coronary
artery lesions (73, 76), but the direct functional relationship
between SR-A and apo A-I in tissues remains to be proven.
Interestingly, the novel ligands identified here are in part derived
from the same macrophages they retain. Repopulation of irra-
diated apo E
-/- mice with either WT or apo E
-/- bone marrow
indicates that macrophage secretion alone is able to reconstitute
plasma apo E levels to approximately 10% (∼130 μg/dL) (77),
sufficient to maintain a normal cholesterol profile in the absence
of metabolic challenge. These studies further show that most
lesion apo E is derived from resident macrophages, as opposed
toinfiltratedplasmalipoproteins.MacrophageapoEsecretionis
stimulated by cholesterol loading and can represent up to 16%
of the total secreted protein (78, 79). It would thus appear that
apo E deposition, SR-A- and apo E-mediated macrophage
retention,foamcellformation,andsubsequentapoEproduction
wouldforma self-propagating loop,exacerbating lesion progres-
sion. While it is technically challenging to determine the exact
lesional concentration of apolipoproteins in vivo, several con-
siderations justify the physiological relevance of apolipoprotein
concentrations used in our in vitro assays. Secreted apo E is
retained and enriched on the surface of macrophages through
interaction with cell surface and extracellular matrix compo-
nents, and constitutive apo E re-uptake and degradation is
slowed by the lysosomal blockage that occurs in foamy macro-
phagessaturatedwithnondegradableoxidizedlipids(80).Hence,
the apo E concentration in the extracellular space surrounding
macrophages mightreachlevelshigher than thosecorresponding
to secretion.Article Biochemistry, Vol. 48, No. 50, 2009 11869
The hypothesis of a pathological role for apo E proposed
aboveisincontradictionwiththeatheroprotectiveroleofplasma
apo E established in hypercholesterolemic apo E
-/- mice (81).
However, it is important to distinguish between peripheral
(macrophage-derived) and hepatic apo E. Indeed, hepatic apo
E plays an essential role in lipoprotein catabolism through its
interaction with hepatic lipoprotein receptors (81), and over-
expression studies suggest that hepatic apo E, rather than
macrophage apo E, is essential in lesion regression through
reverse cholesterol transport (82, 83). In contrast, macrophage-
specificdeletionofapoEinanatherosclerosis-pronebackground
(C57Bl/6) and under metabolic challenge inhibits rather than
enhances atherosclerosis development, consistent with a pro-
atherogenic role of macrophage-derived, local apo E (84).
Along with CD36 and LOX-1, SR-A is one of the major
receptors involved in cholesterol accumulation in macrophages.
Our finding that 4F is able to compete efficiently with modified
LDL suggests it may prevent foam cell formation by inhibiting
oxLDLuptake viaSR-A.The capacityofthesmallpeptide4Fto
abrogate the pro-atherogenic SR-A-mediated processes of
oxLDL binding and adhesion of macrophages to lesional sub-
strata may add therapeutic potential to this molecule, which is
already on the way to medical approval (85, 86). In addition, 4F
provides a useful tool for potentially targeting one class A
scavenger receptor family member specifically, as it is not
recognized bythe classA memberMARCO (S.Mukhopadhyay,
personal communication).
In summary, the identification of exchangeable apolipo-
proteins as novel endogenous ligands for scavenger receptor A
described here raises a number of implications for macrophage
adhesion, lipid homeostasis, and innate immunity.
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Outline of the ligand isolation strategy (Figure 1), plasma
fractionated by ion exchange that contains two SR-A binding
peaks (Figure 2), and mass spectrometry identification of candi-
dateligandsinSR-Abindingbandsfromtwosimilarpurification
runs (Table 1). This material is available free of charge via the
Internet at http://pubs.acs.org.
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